VF Challenor

416 total citations
17 papers, 331 citations indexed

About

VF Challenor is a scholar working on Oncology, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, VF Challenor has authored 17 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in VF Challenor's work include Drug Transport and Resistance Mechanisms (7 papers), Systemic Sclerosis and Related Diseases (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). VF Challenor is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Systemic Sclerosis and Related Diseases (5 papers) and Pharmacological Effects and Toxicity Studies (4 papers). VF Challenor collaborates with scholars based in United Kingdom and United States. VF Challenor's co-authors include DG Waller, CF George, AG Renwick, O.S. Roath, D. G. Waller, A. G. Renwick, DR Robertson, Stephen T. Holgate, Richard Beasley and C F George and has published in prestigious journals such as Drugs, British Journal of Clinical Pharmacology and Clinical Science.

In The Last Decade

VF Challenor

17 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
VF Challenor United Kingdom	13	103	101	83	58	50	17	331
Ulla Lei Larsen Denmark	9	100 1.0×	65 0.6×	90 1.1×	10 0.2×	42 0.8×	18	510
DG Shand United States	10	97 0.9×	73 0.7×	69 0.8×	12 0.2×	64 1.3×	13	424
P. Anderson Sweden	13	68 0.7×	45 0.4×	71 0.9×	11 0.2×	41 0.8×	20	413
A. Pottage United Kingdom	15	74 0.7×	96 1.0×	49 0.6×	17 0.3×	271 5.4×	26	552
David G. May United States	10	105 1.0×	72 0.7×	53 0.6×	20 0.3×	16 0.3×	16	325
L Molin Sweden	12	55 0.5×	19 0.2×	31 0.4×	38 0.7×	50 1.0×	28	368
Esther Salgueiro Spain	10	85 0.8×	46 0.5×	35 0.4×	36 0.6×	24 0.5×	30	396
A Escousse France	10	44 0.4×	32 0.3×	76 0.9×	25 0.4×	23 0.5×	38	295
K. Frislid Norway	14	66 0.6×	68 0.7×	32 0.4×	13 0.2×	56 1.1×	22	516
Dhanashri Kolwankar United States	8	158 1.5×	173 1.7×	66 0.8×	28 0.5×	31 0.6×	8	419

Countries citing papers authored by VF Challenor

Since Specialization

Citations

This map shows the geographic impact of VF Challenor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by VF Challenor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites VF Challenor more than expected).

Fields of papers citing papers by VF Challenor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by VF Challenor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by VF Challenor. The network helps show where VF Challenor may publish in the future.

Co-authorship network of co-authors of VF Challenor

This figure shows the co-authorship network connecting the top 25 collaborators of VF Challenor. A scholar is included among the top collaborators of VF Challenor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with VF Challenor. VF Challenor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Armstrong, J., et al.. (1997). The influence of two types of meal on the pharmacokinetics of a modified-release formulation of nifedipine (Adalat Retard). European Journal of Clinical Pharmacology. 53(2). 141–143. 13 indexed citations

Challenor, VF. (1994). Angiotensin Converting Enzyme Inhibitors in Raynaud??s Phenomenon. Drugs. 48(6). 864–867. 15 indexed citations

Roberts, J A, VF Challenor, & D. G. Waller. (1992). Is xamoterol safe in chronic airflow obstruction?. European Journal of Clinical Pharmacology. 42(2). 147–150. 1 indexed citations

Renwick, AG, et al.. (1992). The influence of posture on the pharmacokinetics of orally administered nifedipine.. British Journal of Clinical Pharmacology. 34(4). 332–336. 31 indexed citations

Renwick, AG, et al.. (1991). Ethnic differences in the pharmacokinetics of oral nifedipine.. British Journal of Clinical Pharmacology. 31(4). 399–403. 52 indexed citations

Donaldson, Kirsteen, et al.. (1991). Effects of Nifedipine and Propranolol on Whole Blood Platelet Aggregation. Platelets. 2(3). 141–143. 2 indexed citations

Challenor, VF, et al.. (1991). Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.. British Journal of Clinical Pharmacology. 31(4). 477–480. 17 indexed citations

Challenor, VF, DG Waller, AG Renwick, & CF George. (1989). Slow release nifedipine plus atenolol in chronic stable angina pectoris.. British Journal of Clinical Pharmacology. 28(5). 509–516. 7 indexed citations

Beasley, Richard, et al.. (1988). Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clinical Science. 74(4). 351–357. 20 indexed citations

10.

Renwick, AG, et al.. (1988). The pharmacokinetics of oral nifedipine‐a population study.. British Journal of Clinical Pharmacology. 25(6). 701–708. 40 indexed citations

11.

Francis, J.L., O.S. Roath, VF Challenor, & DG Waller. (1988). The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.. British Journal of Clinical Pharmacology. 25(6). 751–754. 6 indexed citations

12.

Challenor, VF, D. G. Waller, D A Francis, et al.. (1987). Nisoldipine in primary Raynaud's phenomenon. European Journal of Clinical Pharmacology. 33(1). 27–30. 12 indexed citations

13.

Renwick, A. G., et al.. (1987). Factors affecting the pharmacokinetics of nifedipine. European Journal of Clinical Pharmacology. 32(4). 351–355. 26 indexed citations

14.

Challenor, VF, et al.. (1987). Food and nifedipine pharmacokinetics.. British Journal of Clinical Pharmacology. 23(2). 248–249. 16 indexed citations

15.

Challenor, VF, et al.. (1987). The trans‐hepatic extraction of nifedipine.. British Journal of Clinical Pharmacology. 24(4). 473–477. 31 indexed citations

16.

Waller, DG, et al.. (1986). Clinical and rheological effects of nifedipine in Raynaud's phenomenon.. British Journal of Clinical Pharmacology. 22(4). 449–454. 21 indexed citations

17.

Challenor, VF, et al.. (1986). The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.. British Journal of Clinical Pharmacology. 22(5). 565–570. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact